Dupilumab treatment in patients with CRSwNP led to a healthier nasal microbiota by increasing beneficial bacteria like Lawsonella and Corynebacterium. The gut microbiota showed no effect, indicating dupilumab’s localized impact on nasal inflammation.
The post Microbiota Response to Dupilumab in CRSwNP first appeared on Physician’s Weekly.
